Combined Pegaptanib sodium (Macugen) and photodynamic therapy in predominantly classic juxtafoveal choroidal neovascularisation in age related macular degeneration.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 18156376.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This prospective, open label, non-comparative, observational case series evaluates 6-month results of Pegaptanib Sodium (Macugen) and Photodynamic Therapy (PDT) in predominantly classic juxtafoveal choroidal neovascularisation (CNV) in age-related macular degeneration (AMD) in seven eyes of seven patients. Best corrected visual acuity (BCVA) diminished with a mean of five letters. Initial area of CNV increased significantly from 1.4 mm2 to 2.7 mm2. There was a significant increase in the greatest linear dimension (GLD) from 1280.3 microm to 2065.7 microm at the 24-week follow-up. Predominantly classic juxtafoveal CNVs are highly aggressive lesions that demonstrate poor response despite combined therapy using PDT and Macugen.
Medical subject headings
- Angiogenesis Inhibitors
- Aptamers, Nucleotide
- Choroidal Neovascularization
- Macular Degeneration
- Photochemotherapy